Teva’s Copaxone Maintains a Dominant Presence in the MS Treatment Algorithm

Teva’s Copaxone Maintains a Dominant Presence in the MS Treatment Algorithm among Both Newly Diagnosed and Recently Treated Patients

July 13, 2011 - BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that among recently treated multiple sclerosis (MS) patients in the fourth quarter of 2010, Teva’s Copaxone garnered the highest patient share among key individual MS therapies, while the interferon-beta products as a class captured the largest patient share. Copaxone was also the preferred therapy among newly diagnosed MS patients in both the first and second lines of therapy.

According to Treatment Algorithms in Multiple Sclerosis, Biogen Idec/Elan’s Tysabri saw little use as a first-line therapy among newly diagnosed patients, consistent with its labeling, but experienced a considerable increase in patient share as a second-line therapy. In addition, Tysabri received nearly a 10 percent patient share among recently treated patients in the last quarter of 2010.

“Copaxone’s dominant presence in early lines of MS treatment reflects in part its comparable efficacy to and its tolerability advantage over the interferon-beta products. Moreover, patients who fail an interferon-beta product in the first line may move to Copaxone second-line because of its alternative mechanism of action,” said Decision Resources Analyst Georgiana Kuhlmann, S.M. “Meanwhile, Tysabri’s strong efficacy and excellent tolerability, coupled with the continued need for highly effective treatments, render it an important option for treatment-refractory patients or those with high disease activity.”

Continue reading

===========================================================

Remain CURRENT with Multiple Sclerosis news

 and information, when registered 

at the  MS Views and News website

.

~ Our weekly e-Newsletter is now reaching (87) Countries ~

.

DONATION$  are needed to help us to Educate 

.

"MS Views and News"  is a 501©(3) organization as

recognized by the Internal Revenue Service

All contributions are tax deductible to the fullest extent allowed by law

.

> Providing You with 'MS Views and News', is what we do < 

.===========================================================

Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.